Qbic | Activity | F4
Qbic Activity Every public signal F4 has attached to this firm, with sources and cross-entity links.
Team Change
Portfolio company Tanai Therapeutics appointed Josua Jordi as Chief Executive Officer. Josua Jordi appointed CEO of Tanai Therapeutics
Portfolio company Abscint SA was acquired by Curium. Investment
Qbic III participated in Sightera Biosciences' EUR3M pre-seed round for its patient-derived AI drug discovery platform, alongside Entourage and Anacura. Sightera Biosciences
4 milestones · MAY 2026 – JUN 2026 Show all Milestone
Portfolio companies moveUP and Cascador Health merged to build a combined data-driven digital health platform. moveUP
moveUP Cascador Health Qbic Milestone
Portfolio company Abscint announced compelling clinical results for its HER2-targeted imaging agent, shortly before its acquisition by Curium. Abscint
Milestone
Portfolio company eyeo raised a EUR40M Series A to commercialize its color-splitting image sensor technology. eyeo
Milestone
Portfolio company MRM Health was granted FDA Fast Track designation for its lead asset MH002. MRM Health
Investment
Qbic led AILOS Robotics' EUR3.5M seed round alongside High-Tech Gruenderfonds to scale gearbox manufacturing for next-gen robots. AILOS Robotics